Evidence map›Paper›PMID 40463976›Full record

ReviewFrontiers in medicine2025

Reporter genes and transgenic

Daniele Santana de Sousa Oliveira, Elis Dionisio da Silva, Fábio Farias Galvão Júnior, Danielle Maria Nascimento Moura, Policarpo Ademar Sales-Junior, Maria Carolina Accioly Brelaz-de-Castro, Valéria Rêgo Alves Pereira

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Daniele Santana de Sousa Oliveira *Postgraduation Program in Therapeutic Innovation, Federal University of Pernambuco, Recife, Pernambuco, Brazil.
Elis Dionisio da Silva *Health and Biotechnology Institute, Federal University of Amazonas, Coari, Amazonas, Brazil.
Fábio Farias Galvão Júnior *Postgraduation Program in Therapeutic Innovation, Federal University of Pernambuco, Recife, Pernambuco, Brazil.
Danielle Maria Nascimento MouraImmunopathology and Molecular Biology Laboratory, Aggeu Magalhães Institute (FIOCRUZ-PE), Department of Immunology, Recife, Pernambuco, Brazil.
Policarpo Ademar Sales-JuniorImmunopathology and Molecular Biology Laboratory, Aggeu Magalhães Institute (FIOCRUZ-PE), Department of Immunology, Recife, Pernambuco, Brazil.
Maria Carolina Accioly Brelaz-de-CastroImmunopathology and Molecular Biology Laboratory, Aggeu Magalhães Institute (FIOCRUZ-PE), Department of Immunology, Recife, Pernambuco, Brazil.
Valéria Rêgo Alves PereiraImmunopathology and Molecular Biology Laboratory, Aggeu Magalhães Institute (FIOCRUZ-PE), Department of Immunology, Recife, Pernambuco, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chagas disease is considered a public health issue, especially in Latin America. To this date, the course of the infection caused by the parasite

Indexed as

Chagas diseasedrug screeningreporter genetransgenic parasiteTrypanosoma cruzi

Identifiers

PMID40463976
PMCPMC12129773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.